No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Wednesday, October 29, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Markets

IPO News: MapLight Therapeutics targets 704 mln valuation in Nasdaq debut

by TheAdviserMagazine
3 weeks ago
in Markets
Reading Time: 2 mins read
A A
IPO News: MapLight Therapeutics targets 704 mln valuation in Nasdaq debut
Share on FacebookShare on TwitterShare on LInkedIn


In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain momentum after last year’s record lows.  MapLight Therapeutics, Inc. is the latest healthcare company to jump on the IPO bandwagon, eying a $704 million valuation.

The Offering

In a recent filing with the Securities and Exchange Commission, the company revealed its intention to offer 14.75 million shares in an initial public offering. Post-IPO, the stock is expected to trade on the Nasdaq stock exchange under the symbol MPLT. Morgan Stanley, Jefferies, Leerink Partners, and Stifel are the underwriters managing the offering.

The estimated IPO price is $17 per share, which translates into net proceeds of about $227.3 million after deducting offering expenses and other charges. The company plans to use the proceeds to advance the clinical development of its current programs, to fund research and development activities for additional programs, and for working capital and other general corporate purposes.

Loss Widens

MapLight has not yet generated revenue, since it doesn’t have any product in the market. In the six months ended June 30, 2025, the company incurred a loss of $52.2 million, compared to a loss $37.3 million in the corresponding period last year. Total operating expenses were $54.2 million in the first half.

MapLight is a clinical-stage biopharmaceutical company engaged in the discovery of therapies for central nervous system disorders. Christopher Kroeger, who co-founded the company in 2018, has served as its chief executive officer, president, and member of the board of directors since then.

Clinical Programs

Currently, MapLight is conducting a phase-II trial evaluating its lead product, ML-007C-MA, for the treatment of acute schizophrenia, and expects topline results in the second half of 2026. In addition, it is doing an advanced-stage trial evaluating ML-007C-MA for the treatment of ADP, with topline results expected in the second half of 2027.



Source link

Tags: debutIPOMapLightMlnNasdaqNewsTargetsTherapeuticsvaluation
ShareTweetShare
Previous Post

Foreclosure Auctions Rise 19%, Giving Investors a Chance to Snag Deals

Next Post

Foreign Investors Flock to the U.S. Housing Market, Buying $56B Worth of Real Estate

Related Posts

edit post
Jean Chatzky Warns That Emotional Loyalty Can Derail Retirement Planning as 85% of Americans Admit They Would Risk Financial Security to Help Family

Jean Chatzky Warns That Emotional Loyalty Can Derail Retirement Planning as 85% of Americans Admit They Would Risk Financial Security to Help Family

by TheAdviserMagazine
October 29, 2025
0

Tint Media / Shutterstock.comAdvertising Disclosure: When you buy something by clicking links within this article, we may earn a small...

edit post
Fiserv stock craters 44% after company slashes guidance

Fiserv stock craters 44% after company slashes guidance

by TheAdviserMagazine
October 29, 2025
0

Cheng Xin | Getty Images News | Getty ImagesFiserv's stock plummeted 44% Wednesday and headed for its worst day ever...

edit post
This San Francisco-based satellite company’s stock has doubled in the past three months

This San Francisco-based satellite company’s stock has doubled in the past three months

by TheAdviserMagazine
October 28, 2025
0

Planet Labs stock has been on a tear over the last few months as investors bet on the company's satellite...

edit post
Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

by TheAdviserMagazine
October 28, 2025
0

Investors are noticing ripe opportunity in Cytokinetics, a late-stage biopharma company targeting medicines for specialty heart diseases, that has seen...

edit post
Visa reports higher Q4 revenue and profit; results beat estimates

Visa reports higher Q4 revenue and profit; results beat estimates

by TheAdviserMagazine
October 28, 2025
0

Visa, Inc. (NYSE: V) on Tuesday reported an increase in revenues for the fourth quarter of fiscal 2025, which translated...

edit post
Key highlights from Electronic Arts’ (EA) Q2 2026 earnings results

Key highlights from Electronic Arts’ (EA) Q2 2026 earnings results

by TheAdviserMagazine
October 28, 2025
0

Electronic Arts Inc. (NASDAQ: EA) reported its second quarter 2026 earnings results today. Net revenue decreased 9% year-over-year to $1.84...

Next Post
edit post
Foreign Investors Flock to the U.S. Housing Market, Buying B Worth of Real Estate

Foreign Investors Flock to the U.S. Housing Market, Buying $56B Worth of Real Estate

edit post
Can You Defer Payments on a Business Loan?

Can You Defer Payments on a Business Loan?

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Another Violent Outburst – Democrats Inciting Civil Unrest

Another Violent Outburst – Democrats Inciting Civil Unrest

October 24, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Yunus fears attempts to thwart planned Bangladesh polls

Yunus fears attempts to thwart planned Bangladesh polls

0
edit post
Mastercard poised to acquire crypto startup Zerohash for nearly  billion, sources say

Mastercard poised to acquire crypto startup Zerohash for nearly $2 billion, sources say

0
edit post
Earnings Preview: What to expect when Amazon reports Q3 2025 results

Earnings Preview: What to expect when Amazon reports Q3 2025 results

0
edit post
Israeli web security co Reflectiz raises m

Israeli web security co Reflectiz raises $22m

0
edit post
2025 Dividend Discount Model | Excel Calculator & Examples

2025 Dividend Discount Model | Excel Calculator & Examples

0
edit post
Grokpedia | Armstrong Economics

Grokpedia | Armstrong Economics

0
edit post
Mastercard poised to acquire crypto startup Zerohash for nearly  billion, sources say

Mastercard poised to acquire crypto startup Zerohash for nearly $2 billion, sources say

October 29, 2025
edit post
Yunus fears attempts to thwart planned Bangladesh polls

Yunus fears attempts to thwart planned Bangladesh polls

October 29, 2025
edit post
Coca-Cola Stock Is Already A Great Income Stock. Here’s How To Make It Better.

Coca-Cola Stock Is Already A Great Income Stock. Here’s How To Make It Better.

October 29, 2025
edit post
Jean Chatzky Warns That Emotional Loyalty Can Derail Retirement Planning as 85% of Americans Admit They Would Risk Financial Security to Help Family

Jean Chatzky Warns That Emotional Loyalty Can Derail Retirement Planning as 85% of Americans Admit They Would Risk Financial Security to Help Family

October 29, 2025
edit post
TRON DAO Participates in Europol’s 9th Global Conference on Criminal Finances and Cryptoassets

TRON DAO Participates in Europol’s 9th Global Conference on Criminal Finances and Cryptoassets

October 29, 2025
edit post
Oasis CEO uses AI to create financial plans, stock analyses

Oasis CEO uses AI to create financial plans, stock analyses

October 29, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Mastercard poised to acquire crypto startup Zerohash for nearly $2 billion, sources say
  • Yunus fears attempts to thwart planned Bangladesh polls
  • Coca-Cola Stock Is Already A Great Income Stock. Here’s How To Make It Better.
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.